From what 10 stock analysts predict, the share price for GoodRx Holdings Inc (GDRX) might increase by 12.39% in the next year. This is based on a 12-month average estimation for GDRX. Price targets go from $4.50 to $12.00. The majority of stock analysts believe GDRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
GoodRx Holdings Inc has a total of 10 Wall St Analyst ratings. There are 3 buy ratings, 6 ratings, and 1 sell ratings. Since most analysts have a buy consensus rating, the expectation is that GoodRx Holdings Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
allen lutz Bank of America Securities | Sell | $4.5 | reiterated | Jan 19, 2024 |
GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.
When did it IPO
2020
Staff Count
952
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Market Cap
$2.61B
In 2023, GDRX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that GDRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
JAMF-USD
$20.7
PDCO-USD
$28.35
BEAM-USD
$33.54
PLXS-USD
$95.43
DORM-USD
$82.82
MYRG-USD
$154.12